Neurofilament light chain predicts future dementia risk in cerebral small vessel disease.
Journal
Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R
Informations de publication
Date de publication:
08 Feb 2021
08 Feb 2021
Historique:
received:
18
11
2020
revised:
13
01
2021
accepted:
14
01
2021
entrez:
9
2
2021
pubmed:
10
2
2021
medline:
10
2
2021
Statut:
aheadofprint
Résumé
Serum neurofilament light chain (NfL) has been proposed as prognostic markers in neurogenerative disease. A cross-sectional study in cerebral small vessel disease (SVD) reported an association with cognition and disability. If NfL is to be used to predict outcome, studies are required to demonstrate baseline NfL predicts future dementia risk. Furthermore, if it is to be used as a surrogate marker in clinical trials, change in NfL over time periods typical of a clinical trial must be linked to clinical progression. In a longitudinal study of patients with lacunar stroke and confluent white matter hyperintensities, we determined whether both baseline, and change, in NfL levels were linked to changes in MRI markers, cognitive decline and dementia risk. Patients underwent MRI, cognitive testing and blood taking at baseline and annually for 3 years. Clinical and cognitive follow-up continued for 5 years. NfL data were available for 113 subjects for baseline analysis, and 90 patients for the longitudinal analysis. Baseline NfL predicted cognitive decline (global cognition β Baseline NfL predicts changes in MRI markers, cognitive decline and dementia rate over a 5 years follow-up period in SVD, suggesting NfL may be a useful prognostic marker. However, change in NfL values was not detected, and therefore NfL may not be a useful surrogate marker in clinical trials in SVD.
Identifiants
pubmed: 33558370
pii: jnnp-2020-325681
doi: 10.1136/jnnp-2020-325681
pmc: PMC8142459
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Neuroimage Clin. 2018 Jun 20;19:925-938
pubmed: 30003030
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
JAMA Neurol. 2019 Jan 1;76(1):81-94
pubmed: 30422209
PLoS One. 2016 Jan 25;11(1):e0147836
pubmed: 26808982
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
J Stroke. 2020 Sep;22(3):369-376
pubmed: 33053952
PLoS One. 2015 Aug 14;10(8):e0135523
pubmed: 26273828
Neurology. 2017 Nov 14;89(20):2108-2114
pubmed: 29046363
J Cereb Blood Flow Metab. 2016 Jan;36(1):228-40
pubmed: 26036939
JAMA Neurol. 2017 May 1;74(5):557-566
pubmed: 28346578
J Stroke. 2018 May;20(2):228-238
pubmed: 29886723
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Ann Neurol. 2016 Oct;80(4):581-92
pubmed: 27518166
Nat Commun. 2020 Feb 10;11(1):812
pubmed: 32041951
Scott Med J. 1957 May;2(5):200-15
pubmed: 13432835
Neurology. 2017 Oct 31;89(18):1869-1876
pubmed: 28978655
Neurology. 2016 Sep 27;87(13):1329-36
pubmed: 27581216
Med Image Anal. 2001 Jun;5(2):143-56
pubmed: 11516708
Stroke. 2009 Jan;40(1):94-9
pubmed: 19008468
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
PLoS One. 2013 Sep 20;8(9):e75091
pubmed: 24073237
Neurology. 2018 Oct 2;91(14):e1338-e1347
pubmed: 30217937
Stroke. 1988 May;19(5):604-7
pubmed: 3363593
Lancet Neurol. 2019 Jul;18(7):684-696
pubmed: 31097385
Ann Clin Transl Neurol. 2018 Nov 20;6(1):46-56
pubmed: 30656183